Clinical trial Recruiting at 1 site Phase 2 Interventional Ages 1 Year to 10

Autologous bone marrow cell transplant for spastic cerebral palsy from brain hypoxia

Official title: Evaluation of the Efficacy of Autologous Bone Marrow-Derived Mononuclear Cell Transplantation in the Treatment of Cerebral Palsy Due to Brain Hypoxia: A Phase II Randomized Clinical Trial

Run by Vinmec Research Institute of Stem Cell and Gene Technology · NCT06629324 · Data updated 2026-11-12

This trial will try giving children aged 1 to 10 with spastic cerebral palsy caused by brain hypoxia an infusion of their own bone marrow mononuclear cells to see if their movement and muscle tightness improve.

More Autism Spectrum Disorder trials

Quick facts

PhasePhase 2
Study typeInterventional
Ages1 Year to 10 Years
SexAll
Enrollment58 (estimated)
SponsorVinmec Research Institute of Stem Cell and Gene Technology
Academic / other
Locations2 sites (Hanoi and 1 other locations)
StatusRecruiting
StartedOctober 15, 2024
Main results expectedOctober 15, 2026
Study endsJanuary 31, 2027
Registry record updatedJanuary 22, 2026
Trial IDNCT06629324 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Children aged 1 to 10 with spastic cerebral palsy caused by brain hypoxia and GMFCS level II–V who are medically stable and meet laboratory and safety criteria are ideal candidates.

Probably not a fit

Children with non-hypoxic or non-spastic cerebral palsy, severe organ failure, active infections, coagulation disorders, spinal conditions preventing intrathecal procedures, or who fail hemoglobin and other safety thresholds are unlikely to benefit or be eligible.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase II randomized trial will enroll 58 children aged 1–10 with spastic cerebral palsy due to brain hypoxia and GMFCS levels II–V at Vinmec in Hanoi. Participants will be randomly assigned to receive autologous bone marrow mononuclear cell transplantation plus rehabilitation or a control regimen, with treatments delivered per protocol and follow-up visits over nine months after the first transplantation. Safety outcomes include monitoring adverse events and serious adverse events, and efficacy outcomes include changes in GMFM-88, GMFCS, Modified Ashworth Scale, and MACS/Mini-MACS scores. The trial builds on a Phase I safety study and aims to quantify functional gains and tone changes under standardized rehabilitation.

Why it matters

Potential benefit: If successful, this approach could reduce muscle spasticity and improve gross motor function and daily mobility for children with hypoxic spastic cerebral palsy, potentially improving quality of life.

How similar studies have gone: Small early-phase trials and the investigators' Phase I study have reported safety and some motor improvements with autologous bone marrow mononuclear cell therapy, but randomized evidence in larger samples is still limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age from 1 to 10 years, both genders;
* Gross Motor Function Classification System (GMFCS): levels II to V;
* Spastic cerebral palsy due to brain hypoxia.

Exclusion Criteria:

* Coagulation disorders;
* Severe health conditions such as cachexia, heart failure, lung, liver, or kidney failure; or active infections;
* Spinal injuries prevent the placement of a catheter through the spinal cavity;
* Cancer;
* HIV positive, active viral hepatitis;
* Hemoglobin below 110 g/L.

Where it's running

  • Vinmec research Institute and Gene Technology
    Hanoi, Vietnam
    Recruiting
  • Vinmec Research Institute of Stem Cell and Gene Technology
    Hanoi, Vietnam
    Not yet recruiting

Study contacts

  • Principal investigator: Liem T Nguyen, MD., PhD — Vinmec Research Insitute of Stem Cell and Gene Technology
  • Study coordinator: Liem T Nguyen, MD, PhD
  • Email: v.liemnt@vinmec.com
  • Phone: 800-555-5555

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.